San Francisco startup Framework Therapeutics is likewise focusing on an oral, when-daily GLP-1 drug named GSBR-1290—the drug surpassed Wall Avenue’s expectations in June whenever a mid-stage research confirmed common weight loss of close to 6% and it programs to start out One more mi